Alcyone Lifesciences (Lowell, MA) obtained FDA clearance for the Alcyone MEMS Cannula, a dual lumen bratin injection and aspiration device that can be used under MRI.

The device is intended for use in delivering gene therapy, therapeutic viruses, and other new ways of treating central nervous system disorders.

“The AMC was developed using our game-changing proprietary microelectromechanical system (MEMS) platform. Without burdening the neurosurgery community with unnecessary additional capital equipment, the AMC can be utilized with any existing commercial imaging and stereotactic system. Neurosurgeons can select a target, navigate the AMC precisely to the target, and observe in real-time the precision delivery of the therapeutic agent, all under intra-procedural MRI guidance”, said Deep Singh, Director of Product Development at Alcyone Lifesciences, in a statement. “In addition to the MEMS tip which has dual micro-channels, the AMC features a unique patented distal end design that helps prevent reflux or back flow along the cannula shaft, which can be a significant drawback with current devices. The AMC platform device is designed for optimal targeted bio-distribution and neurosurgeon’s ease of use”.

source:Alcyone Lifesciences